A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Azacitidine; Azacitidine
  • Indications Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Acronyms SUPPORT
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 06 Dec 2016 Primary endpoint of proportion of platelet-transfusion independent patients during AZA cycles 1-4 has not been met, according to results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 13 Jul 2016 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top